| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 07/13/2005 | EP1551822A2 Pentacyclic oxepines and derivatives thereof, process for their preparation and pharmaceutical compositions containing them |
| 07/13/2005 | EP1551812A2 Mitotic kinesin inhibitors |
| 07/13/2005 | EP1551803A1 Azabicyclo derivatives as muscarinic receptor antagonists |
| 07/13/2005 | EP1551802A1 Indole-3-sulphur derivatives |
| 07/13/2005 | EP1551793A1 Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same |
| 07/13/2005 | EP1551791A1 Novel salt forms of poorly soluble probucol esters and ethers |
| 07/13/2005 | EP1551763A1 Method for the preparation of a silicic acid comprising extrudate, said extrudate, its use and a pharmaceutical composition comprising the said extrudate |
| 07/13/2005 | EP1551461A2 Azo compounds for type i phototherapy |
| 07/13/2005 | EP1551452A1 Compositions and methods for therapeutic treatment |
| 07/13/2005 | EP1551440A2 Uses of human zven proteins and polynucleotides |
| 07/13/2005 | EP1551436A2 Formulations for amylin agonist peptides |
| 07/13/2005 | EP1551434A2 Identification of actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases |
| 07/13/2005 | EP1551431A2 Purified amylase inhibitor and novel process for obtaining the same |
| 07/13/2005 | EP1551421A2 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| 07/13/2005 | EP1551416A2 Method for treating erectile dysfunction and increasing libido in men |
| 07/13/2005 | EP1551412A1 Pharmaceutical compositions for the treatment of diseases related to neurotrophines |
| 07/13/2005 | EP1551397A2 Guanidine compounds as anesthetics and for treatment of nervous system disorders |
| 07/13/2005 | EP1551394A1 Treatment of lower urinary tract symptoms associated with overactive bladder in men and women |
| 07/13/2005 | EP1551387A2 PKC ACTIVATION AS A MEANS FOR ENHANCING sAPPa SECRETION AND IMPROVING COGNITION USING BRYOSTATIN TYPE COMPOUNDS |
| 07/13/2005 | EP1551369A2 Combination therapy for treatment of fibrotic disorders |
| 07/13/2005 | EP1551228A2 Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases |
| 07/13/2005 | EP1448529B1 Sulfone derivatives suitable for the treatment of autoimmune diseases and allergies |
| 07/13/2005 | EP1427711B1 Oxazolidinone and/or isoxazoline derivatives as antibacterial agents |
| 07/13/2005 | EP1266039B1 Method and kit for the screening, the detection and/or the quantification of transcriptional factors |
| 07/13/2005 | EP1248636B1 Dextrin containing compositions for prevention of adhesions |
| 07/13/2005 | EP1235802B1 Carbamate derivatives having muscarinic receptor antagonist activity |
| 07/13/2005 | EP1161415B1 N-cyanomethylamides as protease inhibitors |
| 07/13/2005 | EP1001976B1 Peptides having potassium channel opener activity |
| 07/13/2005 | EP0977755B1 Heterocyclic compounds and their preparation and use |
| 07/13/2005 | CN1639569A Methods and compositions for inducing an immune response |
| 07/13/2005 | CN1639325A A method for producing recombinant viruses using site-specific recombination |
| 07/13/2005 | CN1639195A Selective targeting of tumor vasculature using antibody molecules |
| 07/13/2005 | CN1639190A Transmembrane NFAT inhibitory peptide |
| 07/13/2005 | CN1639188A Hepta-, octa- and nonapeptides having antiangiogenic activity |
| 07/13/2005 | CN1639187A Macrocyclic peptides active against the hepatitis C virus |
| 07/13/2005 | CN1639186A Inhibitors of kallikrein |
| 07/13/2005 | CN1639185A Cancer-associated epitope |
| 07/13/2005 | CN1639180A Aryl 5-thio-beta-D-glucopyranoside derivatives and remedies for diabetes containing the same |
| 07/13/2005 | CN1639168A Bicyclic pyridine and pyrimidine P38 kinase inhibitors |
| 07/13/2005 | CN1639165A Purine derivatives as kinase inhibitors |
| 07/13/2005 | CN1639164A Nitrogen-containing heterocyclic compound |
| 07/13/2005 | CN1639161A Alkyne-aryl phosphodiesterase-4 inhibitors |
| 07/13/2005 | CN1639159A N-aminoacetyl-pyrrolidine-2-carbonitriles and their use as DDP-IV inhibitors |
| 07/13/2005 | CN1639158A Thiazole derivatives as NPY receptor antagonists |
| 07/13/2005 | CN1639157A 2-acylaminothiazole derivative or salt thereof |
| 07/13/2005 | CN1639156A 8'4-'3-(5-fluoro-1H-indol-3-yl)propyl!-1-piperazinyl!-2-methyl-2H-1, 4-benzoxazin -3(4H)-one methanesulfonate with high affinity for the dopamine D2 receptor and the seotonin reuptake site |
| 07/13/2005 | CN1639155A Pyrrolidine oxadiazole- and thiadiazole derivatives |
| 07/13/2005 | CN1639154A Pyranones useful as ATM inhibitors |
| 07/13/2005 | CN1639152A Pyrrole-2, 5-dione derivatives and their use as GSK-3 inhibitors |
| 07/13/2005 | CN1639151A Novel azepane derivatives |
| 07/13/2005 | CN1639150A 异喹啉衍生物 Isoquinoline derivatives |
| 07/13/2005 | CN1639142A Method for producing 3-amidinophenylalanine derivatives |
| 07/13/2005 | CN1639139A 5-phenylthiazole derivatives and use as PI3 kinase inhibitors |
| 07/13/2005 | CN1639136A Oxazolidinone and/or isoxazoline as antibacterial agents |
| 07/13/2005 | CN1639130A Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same |
| 07/13/2005 | CN1639125A New inhibitors of histone deacetylase |
| 07/13/2005 | CN1639124A Aminotetralin derivatives as muscarinic receptor antagonists |
| 07/13/2005 | CN1639119A Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors |
| 07/13/2005 | CN1639115A Semicarbazide derivatives and their use as antithrombotics |
| 07/13/2005 | CN1638823A N-{5-[4-(4-methyl-piperazino-methyl)--benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine coated stents |
| 07/13/2005 | CN1638805A Pharmaceutical formulation of IRESSA comprising a water-soluble cellulose derivative |
| 07/13/2005 | CN1638801A Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof |
| 07/13/2005 | CN1638799A Human mast cell-expressed membrane proteins |
| 07/13/2005 | CN1638797A Cancer treatment |
| 07/13/2005 | CN1638793A Pharmaceutical and cosmetic compositions comprising PLGF-1 |
| 07/13/2005 | CN1638792A FGFR agonists |
| 07/13/2005 | CN1638790A Compositions and methods for modulating connexin hemichannels |
| 07/13/2005 | CN1638784A External compositions for the skin |
| 07/13/2005 | CN1638779A Utilization of phosphatidylserine in the treatment of attention deficit syndrome (ADHS) |
| 07/13/2005 | CN1638776A Substituted 3-aryl-5-aryl-[1, 2, 4]-oxadiazoles and analogs |
| 07/13/2005 | CN1638775A Nitric oxide donors for treatment of disease and injury |
| 07/13/2005 | CN1638772A Anti-viral compounds |
| 07/13/2005 | CN1638771A Form of presentation for 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] propionic acid ethyl ester to be administered oral |
| 07/13/2005 | CN1638769A Ophthalmic composition comprising ascomycin |
| 07/13/2005 | CN1638767A Combinations comprising epothilone derivatives and alkylating agent |
| 07/13/2005 | CN1638766A Use of substituted 3-phenyl-5-alkoxy-1, 3, 4-oxdiazole-2-one for producing medicaments that inhibit pancreatic lipase |
| 07/13/2005 | CN1638763A Antidepressant |
| 07/13/2005 | CN1638762A Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists |
| 07/13/2005 | CN1638761A Azetidine derivatives as CCR-3 receptor antagonists |
| 07/13/2005 | CN1638760A Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin |
| 07/13/2005 | CN1638759A Pharmaceutical composition comprising a bisphosphonate and a COX-2 inhibitor for the treatment of bone diseases |
| 07/13/2005 | CN1638758A Stimulation of CPT-1 as a means to reduce weight |
| 07/13/2005 | CN1638757A 组织蛋白酶半胱氨酸蛋白酶抑制剂 Cathepsin cystatin |
| 07/13/2005 | CN1638755A Body temperature elevating agents |
| 07/13/2005 | CN1638753A Potentiation of therapeutic effects of fatty acids |
| 07/13/2005 | CN1638751A Use of folates for producing a preparation suitable for preventing and treating inflammation and diseases associated with inflammation, especially for influencing the inflammation markers CRP and SAA |
| 07/13/2005 | CN1638747A Sustained release pharmaceutical composition |
| 07/13/2005 | CN1638739A Compound for treating assuetude disturbance |
| 07/13/2005 | CN1638730A Formoterol superfine formulation |
| 07/13/2005 | CN1638729A Pressurised metered dose inhalers containing solutions of beta-2 agonists |
| 07/13/2005 | CN1638650A Composition improving age-related physiological deficits and increasing longevity |
| 07/13/2005 | CN1637416A Fp-ghrelin |
| 07/13/2005 | CN1637018A Novel effectors of dipeptidyl peptidase IV |
| 07/13/2005 | CN1636994A Process of preparing alkali metal salys of hydrophobic sulfonamides and alkali metal salt produced thereby |
| 07/13/2005 | CN1636992A Process for producing quinazoline ditosylate salt compounds |
| 07/13/2005 | CN1636991A Sodium-hydrogen exchanger type 1 inhibitor crystals |
| 07/13/2005 | CN1636986A Benzophenones as inhibitors of reverse transcriptase |
| 07/13/2005 | CN1636985A Benzophenones as inhibitors of reverse transcriptase |
| 07/13/2005 | CN1636984A Benzophenones as inhibitors of reverse transcriptase |
| 07/13/2005 | CN1636983A Substituted heterocyclic compounds |